Monday, 30 September 2019

BioLargo Spotlight: An Update on BioLargo’s Spiral AOS

Where's the Spiral AOS?
BioLargo’s proprietary, innovative water treatment technology the Advanced Oxidation System (AOS) is already in use in field demonstration pilots (which you can read about here!) and is even gearing up for its first commercial trial. If you’ve been following news about BioLargo’s AOS closely, you might ask “where is that Spiral AOS we heard about, and why don’t I see it at these pilots?” Today we have an update to answer that question.

For those unfamiliar with the Spiral AOS – months past we released a blog post explaining the concept of the Spiral AOS and its relevance to the future of this technology. In short, it’s smaller, more efficient, more affordable for future customers, and performs just as well or better than the traditional “stacked” AOS. At the time of that blog post, we didn’t have great side-by-side comparison images for the Spiral AOS, which made it difficult for some people to grasp the difference between the two types of AOS – that changes today.

We’re happy to say that we now have a Spiral AOS prototype reactor working side-by-side with a traditional stacked AOS at our demonstration pilot at Sunworks Farm. Why this configuration? This lets us compare the Spiral AOS to the Stacked AOS in an apples-to-apples way, allowing us to generate field performance and cost data for both types of AOS units in an industrial setting, thereby paving the way for commercial trials and future sales for either type of AOS reactor.

You can see the Spiral Demonstration Pilot prototype here (image below). As you can see, it’s dramatically smaller than the Stacked prototype. This makes it perfect for future applications where physical space is a consideration, like indoor industrial settings and even future home use settings.

Spiral AOS pictured left. Traditional Stacked AOS pictured right.




















Why would anyone use a Stacked AOS model if the Spiral is so much smaller? In contexts where space is not important (e.g., in outdoor or semi-outdoor agricultural or livestock settings), the Stacked AOS can perform just as well as the Spiral and offer lower maintenance costs for the customer because of its simpler geometry and inner components. By developing these two different models, we can offer our customers more options, helping them solve their water treatment issues in a flexible, affordable, pragmatic way. And in the end, that’s our goal at BioLargo – to help solve customers’ water challenges.

Was this blog post helpful, informative, or interesting? Let us know on social media at:

What is a BioLargo Spotlight?
It’s an exciting time at BioLargo. We’re moving fast, and it can be difficult to keep our stockholders and the investing public informed of our progress. In light of this, we will be posting a series of short articles titled “BioLargo Spotlight”, highlighting certain business activities and other important information in between our required SEC filings. Of course, these do not replace our public filings, which contain more complete information than can be delivered in this forum, and thus we urge you to carefully read and rely on those filings for definitive information, and to review our risk factors and caution regarding forward-looking statements. We are optimistic about our business as we work hard to continue to grow and ultimately generate profits for our stockholders.  

Legal Disclaimer
Our attorneys remind us that while we believe these developments are important and that these small victories could add up and lead to big victories, at this stage they do not rise to the level of an official material disclosure. As the size and magnitude of these developments become material, we will naturally report that information in an 8-K and our regular SEC filings.

Friday, 27 September 2019

Full Proactive Investors interview: BioLargo firing on all cylinders within its engineering, water, medical, and odor subsidiaries

Source: Proactive Investors - https://ca.proactiveinvestors.com/companies/news/903690/biolargo-firing-on-all-cylinders-within-its-engineering-water-medical-and-odor-subsidiaries-903690.html



BioLargo Inc (OTCMKTS:BLGO) CEO Dennis Calvert tells Proactive the company this week formed a strategic alliance with BKT Company Limited, to explore opportunities for the company's CupriDyne Cleane Industrial Odor technology to be used to treat a South Korean city's water and wastewater problems. Along these same lines, its water subsidiary, BioLargo will also begin working with its first customer Sunworks Farm, to treat wastewater on its property with its Advanced Oxidation System.

What's more, Calvert says the California-based company's medical division has gained 510k clearance from the FDA to market its Cyra Wound Irrigation Solution. Calvert also updated on the company's engineering efforts with its US Air Force subcontract.

Thursday, 26 September 2019

Edison Investment Research Update: Clyra gets 510(k) clearance

Edison Investment Research Group published a special update about BioLargo today through their international distribution channels. The update focuses on Clyra's recent FDA 510(k) clearance and its significance to BIoLargo's future growth prospects. This note is a great place to start if you want to understand what the Clyra 510(k) clearance means for the future of these medical products.

You can read the full report at their website HEREand you can also access their original analyst report on BioLargo HERE.







**********************

BioLargo announced on 23 September 2019 that it received 510(k) marketing clearance for the Clyra Wound Irrigation Solution developed by the Clyra Medical subsidiary. The product uses antimicrobial technology based on the delivery of iodine using chemistry similar to the other products developed by BioLargo. The product is designed for cleansing, irrigation and debridement of skin lesions (partial and full thickness) and burns (1st and 2nd degree). With this clearance, the company is free to market and distribute the product, with the ultimate goal of Clyra operating as an independent wound-care company.

Bringing new technology to an established practice

Iodine has a long history in medicine and is an indispensable element of modern practice in the povidone iodine formulation (eg Betadine). However, despite its widespread use, povidone iodine is not without side effects and can cause irritation to mucous membranes and exposed tissue, and is therefore limited to topical use. The Clyra Wound Irrigation Solution instead generates small quantities of reactive iodine in situ that are too low to cause the irritation associated with other formulations (or even risk of staining), but sufficient to provide antiseptic benefit.

Product can be sold nationwide now

The 510(k) clearance means that Clyra is free to sell the product throughout the US or license it to another party for distribution. Products cleared through the 510(k) pathway must show substantial equivalence to an already approved product and not raise any additional safety or effectiveness concerns. We find it encouraging that the FDA upon examination of the data did not foresee any of these concerns with this product, but the details of the medical claims are forthcoming. We expect it to be an attractive product addressing some of the limitations of traditional iodine.

What’s next: An independent wound-care company


BioLargo has repeatedly stated its intent to spin off Clyra as an independent wound-care company, and 510(k) clearance is the first step in that process. There is little operational overlap between Clyra and the other aspects of the business, so this strategy makes sense. Moreover, the company has sought to independently finance Clyra, as the majority (59%) is owned by outside shareholders. Clyra has sought to establish a pipeline outside of the current product and in 2018 purchased the intellectual property of the SkinDisc technology, a regenerative product for wound healing. Finally, it has proposed a series of follow-on indications for the wound-care solution, including dental and orthopedic applications.

BioLargo Signs Memorandum of Understanding with BKT, Tomorrow Water and City of Daegu

Westminster, CA – September 26, 2019 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced that it has signed a Memorandum of Understanding (MOU) with BKT Co. Ltd (and its US subsidiary Tomorrow Water), and the City of Daegu, South Korea. The MOU represents the formation of a strategic alliance aimed at exploring opportunities for BioLargo’s technologies in the water and wastewater industry of South Korea. The MOU calls for an initial focus by the group on seeking clients to utilize BioLargo’s disruptive odor and VOC control product, CupriDyne® Clean, in South Korea’s wastewater treatment industry.

BKT Co. Ltd (www.bkt21.com) is a major wastewater treatment solutions provider in South Korea and Vietnam which prides itself in developing and adopting innovative, environmentally friendly technologies and practices. The City of Daegu, nicknamed South Korea’s Hub of Creative Economy, is developing a regional water innovation cluster aimed at fostering the development and deployment of novel, disruptive technologies into South Korea and Asia’s water industry, intending to create a future “global hub” for water industries. Daegu’s mayor, Kwon Young-jin, was present to sign the MOU at the signing ceremony, which took place at WEFTEC 2019.  

President of BioLargo’s Odor-No-More subsidiary Joseph Provenzano commented, “We hold BKT in the highest esteem. It is a technological innovator and is well-regarded for its leadership in water and wastewater science. This strategic alliance is a result of our successful trials managing odors in hog production and livestock wastewater facilities, BKT’s testing of our product at their Korean facilities, and their recognition of the potential for CupriDyne® Clean to solve odor and VOC control challenges in an affordable, environmentally friendly way.”

BioLargo President & CEO Dennis P. Calvert commented, “Although South Korea and Asia is an enormous opportunity for our technology, we want to be very careful with whom we choose to partner in that market. BKT has an unparalleled reputation in Korea and the confidence of the City of Daegu.”

The CEO of Tomorrow Water (www.tomorrowwater.com), Dong Woo Kim, commented, “It is our pleasure to introduce a safe and environmentally friendly odor control product into the Korean market. We believe this will lead to other big Asian markets, and by leveraging the communication channel and network that the City of Daegu has, this will be a very possible scenario. There is also the potential for us to introduce BioLargo’s AOS (Advanced Oxidation System) into Korea’s wastewater treatment industry by utilizing the experience and network that BKT has. We see lots of collaboration potential between the two entities."

Pictures and video from the MOU signing ceremony:


























About Tomorrow Water and BKT 

Tomorrow Water is a solutions provider for water and energy.


We are founded on the framework that we can minimize the environmental impact of wastewater treatment through sustainable and profitable processes.
Our strength lies in our diverse portfolio of technologies and our people. With our dedicated team of researchers and engineers, we’re able to overcome the challenges faced in wastewater treatment, while maximizing economic benefits by promoting local tourism, decreasing energy costs, and generating direct income sources in the form of carbon credits and advanced energy production.
We are committed to solving the world’s challenges of today, while designing comprehensive solutions for the needs of tomorrow. We offer comprehensive consulting, engineering, operating, and financing services and solutions for each and every client.

Link to BKT and Tomorrow Water Corporate Presentation


About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information
Dennis Calvert President and CEO BioLargo, Inc. Dennis.Calvert@BioLargo.com

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Tuesday, 24 September 2019

BioLargo Water and Sunworks Farm Preparing for First Commercial AOS Trial

Westminster, CA, Sept. 24, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced that its subsidiary BioLargo Water has been asked by Sunworks Farm to submit a proposal to install an AOS water treatment system as part of a commercial trial to manage and treat their water and wastewater farm-wide. This will be the first-ever commercial trial for the AOS technology, marking a pivotal moment in the commercialization of BioLargo’s proprietary technology.

Ron and Sheila Hamilton, owners of Sunworks Farm, commented, “Our experience with BioLargo Water’s pre-commercial pilot for their AOS water treatment system has been exceptional. Their technology clearly works, and their team is a pleasure to work with. We believe that the AOS will enable producers like us to manage water and wastewater in the most environmentally sensitive and economical way possible. We have asked BioLargo Water to develop a proposal for a full-scale commercial trial for their AOS and accompanying proprietary treatment train to manage all water and wastewater at our farm, with the aim of achieving near 100% water reuse. We look forward to working hand-in-hand with their team to establish their technology as part of a new benchmark for environmental stewardship in water conservation in the North American livestock industry.”

BioLargo Water staff are preparing a proposal for the commercial trial AOS unit and treatment train, and we expect them to deliver this proposal to Sunworks soon. BioLargo management plans to release more information about this development as things progress.

About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information
Dennis P. Calvert 
President & CEO, BioLargo, Inc. 
888-400-2863

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Monday, 23 September 2019

BioLargo Subsidiary Clyra Medical Technologies Receives FDA 510(k) Clearance

WESTMINSTER, CA, Sept. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioLargo, Inc. (OTCQB: BLGO), developer of sustainable products and technologies and a full-service environmental engineering company, today announced that its subsidiary Clyra Medical Technologies has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) to market its Clyra Wound Irrigation Solution, designed for cleansing, irrigating, and debriding dermal wounds and burns, in addition to moistening and lubricating absorbent wound dressings. It is the first of multiple products that will feature the company’s platform antimicrobial technology, which offers a unique solution by providing sustained antimicrobial efficacy (including biofilm) without causing harm to tissue.  

President of Clyra, Mr. Steve Harrison, commented, “This is a pivotal milestone in our mission to build a world-class portfolio of unique products and solutions to help heal patients. This FDA clearance is a critical step in the development of our product portfolio and the execution of our commercial strategy. Next up are clinical trials for high-value applications for this platform product.”  

BioLargo President & CEO Dennis P. Calvert commented, “Clyra is a shining star and is destined to bring to market a complete menu of meaningful technical solutions to help heal wounds and prevent and resolve infections around the world. This news illustrates our dedication to carry high-impact technology solutions from concept to completion as we strive to solve pressing issues affecting countless people across the planet. We are thankful for the inspiration of our founder Kenneth Reay Code, the tireless determination and expertise of the team at Clyra, and of course our loyal investors that make all this possible.”


About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic wounds to promote infection control and regenerative tissue therapy.

Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Contact Information
Dennis P. Calvert 
President & CEO, BioLargo, Inc. 
888-400-2863

Friday, 20 September 2019

Good News- Clyra Medical Receives FDA Clearance

Great News! 

Clyra received FDA 510(k) clearance today-

We wanted to get the news out quickly, and we will have a more comprehensive press release out Monday morning at market open. 

#GoBioLargo #GoClyra #Thankful 

Dennis P. Calvert
President & CEO
BioLargo, Inc.

Tuesday, 17 September 2019

ICP-Funded Collaborative Demonstration Pilot Project at Craft Brewery Validates Wastewater Disinfection Performance of BioLargo’s AOS in Field Setting


In April this year (2019), BioLargo’s subsidiaries BioLargo Water and BioLargo Engineering, Science & Technologies installed an Advanced Oxidation System (AOS) unit at a craft brewery in Joshua Tree, CA, as part of a pre-commercial demonstration pilot project. The AOS was installed as part of a treatment train including the BioElectrochemical Treatment Technology (BETTTM) designed and manufactured by BioLargo’s collaborator in the project, AquaCycl. This demonstration pilot, funded by the Innovative Conservation Program (ICP), aimed at treating the brewery’s wastewater with the AOS and BETTTM systems to California’s wastewater discharge standards and avoid non-compliance for the brewery. AquaCycl’s BETTTM provided low-energy primary treatment of wastewater, and the AOS provided low-energy, high performance disinfection of wastewater.

Our work on this pilot project has now concluded! In this pilot, the disinfection capabilities of BioLargo’s AOS were validated in a real-world industrial context, and the AOS performed well in its low-energy disinfection role at the brewery. We are thankful to have had this amazing opportunity to work with our partner Aquacycl in this project, and look forward to other potential opportunities in the future to tackle tough wastewater treatment challenges with them. Our engineering team (BLEST) gained significant understanding of Aquacycl’s innovative new technology and expect that the BETTTM has significant potential to provide value in energy efficient wastewater treatment for food & beverage applications.

The pilot provided valuable “techno-economic” data about the AOS, enabling BioLargo’s engineers to pinpoint the technology’s long-term disinfection performance, operational cost metrics, and create data sets useful for marketing the AOS to future customers. The pilot was particularly important for the AOS as it helped demonstrate that the AOS is capable of functioning in wastewater treatment applications where the input water is especially laden with organic contaminants (as is common with breweries). The high degree of challenge inherent in this wastewater allowed BioLargo engineers to “stress test” the AOS, providing crucial intel to inform the design and optimization of commercial AOS units and enabling the company to execute future pilots and commercial trials successfully.

BioLargo Water President Dr. Richard Smith commented, “We would like to thank TMA BlueTech (formerly The Maritime Alliance) for helping BioLargo Water connect with Aquacycl for this pilot project, which was a tremendous boon for our efforts to commercialize the AOS. This project illustrates the power of technology cluster organizations, especially TMA BlueTech which provides its members with terrific networking support.”

This pilot project also offered an opportunity for BioLargo Engineering, Science & Technologies (BLEST) to provide wastewater treatment engineering services to the craft brewery, potentially paving the way for additional industrial food & beverage wastewater clients for BLEST. Given the increasing pressure put on industrial facilities to manage and reduce their wastewater, and the increasing cost of fresh water globally, breweries and similar food & beverage facilities stand to benefit greatly from BLEST’s wastewater engineering services.

BLEST President Randall Moore commented on the task of treating this craft brewery’s wastewater, “Many small craft breweries like this one contend with tougher standards than large brewers. These requirements posed significant technical and economic challenges to the enterprise, and we at BLEST are more than pleased that we could provide components for a system that will ensure compliance with minimal maintenance, operational costs and capital outlay.  While the situation at this particular brewer was unique, it provided valuable data and experience in the craft brewery industry. We look forward to future challenges and opportunities across the industry and with small generators across the country”.


About BioLargo, Inc.
BioLargo, Inc. is an innovative technology incubator and environmental engineering company driven by a mission to “make life better” by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We incubate disruptive technologies by providing the capital, support, and expertise to expedite them from “cradle” to “maturity” (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System “AOS”, a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About Aquacycl, LLC.
Founded in 2016 and headquartered in San Diego, California, Aquacycl (www.aquacycl.com), Aquacycl provides the only technology for onsite wastewater treatment plants that can eliminate up to 80% of primary sludge, recover energy as direct electricity (no methane), and enable onsite water reuse at operational costs that are 50%-95% lower than incumbent technologies for high-strength wastewater. Aquacycl offers the only technology for treating chemical oxygen demand concentrations up to 100,000 ppm and eliminating total suspended solids up to 3,000 ppm for organic waste streams. Aquacycl’s modular and scalable treatment systems help customers save capital through competitive equipment rental and the Aquacycl service plan guarantees discharge quality per customer requirements.

About TMA BlueTech
TMA BlueTech (www.themaritimealliance.org), previously The Maritime Alliance, is the non-profit industry association and cluster organizer for the San Diego maritime technology community. Its tag line is Promoting BlueTech and Blue Jobs®. We believe in creating BlueTech and Blue Jobs by promoting sustainable, science-based ocean and water industries. We bring education, policy and technology resources together to promote innovation and economic development in the Blue Economy. We create a strong Blue Voice via unique events, information sharing, national and international outreach, networking, research, and workforce development. Our sister non-profit, TMA Foundation focuses on workforce development (including our signature OceanSTEM program), research and community outreach. Its tag line is Fostering Innovation through Collaboration®. The joint Mission of TMA BlueTechand TMA Foundation is to promote sustainable, science-based ocean and water industries.

Friday, 13 September 2019

Edison Investment Research Writes Update on BioLargo for Second Quarter 2019

Edison Investment Research Group published an update on BioLargo, Inc. internationally through their distribution channels on September 6th.

You can read the full report at their website HEREand you can also access their original analyst report on BioLargo HERE.











**********************

BioLargo is close to breaking even with both its Odor-No-More (ONM) and BioLargo Engineering Science & Technology (BLEST) divisions, which reported Q219 operating losses of $51,000 and $27,000, respectively (after $315,000 and $241,000 in revenue). Both businesses have been expanding with new contracts, which we expect to continue to improve margins. ONM recently signed its fourth national distribution agreement, and BLEST was awarded a series of environmental services contracts for US Air Force bases. The company continues to guide to ONM breaking even by YE19.

BLEST to work on USAF bases

Although margins for BLEST are improving, a large portion of its revenue is from services for other BioLargo companies ($130,000 in Q2). However, external contracts continue to expand and BioLargo announced in July 2019 that BLEST would be providing a series of environmental engineering services on US Air Force bases. The company is subcontracting the work from Bhate Environmental Associates, which won the $15m bid. BLEST is responsible for air quality compliance and is continuing to try and win other subcontract bids on the project.

CupriDyne Clean works in cannabis study

ONM has targeted the booming cannabis industry as a potential future customer for its CupriDyne Clean odor control products. As part of this, the company commissioned a third party to provide a proof-of-principle study on the product’s ability to eliminate the odor-causing cannabis terpenes from the air. The study found that the product eliminated the terpenes that were tested (myrcene and limonene) to levels below the limit of detection. Additionally, the company recently reported that its distribution partner Mabre Air Systems has made its first system installation, as well as a number of commercial trials.

AOS poultry and livestock pilot working well

In a true real-world test of BioLargo Water’s Advanced Oxidation System, the company installed a pilot treatment train in Alberta. The system that was placed is a complete treatment train (which includes the AOS as a component) and the company reported that the system is working exceptionally well and providing a statistically significant disinfection performance. Additionally, BioLargo Water announced that it has received a $189,000 grant to open an additional pilot for storm wastewater in Southern California, and BLEST won a grant for $100,000 from the EPA to explore the removal of polyfluoroalkyl substances (PFAS) from waste water, a major water contamination concern.